Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9,528 Mln
Revenue (TTM)
$369 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
14.6
Industry P/E
--
EV/EBITDA
-20.7
Div. Yield
0 %
Debt to Equity
-1.9
Book Value
$--
EPS
$-5.8
Face value
--
Shares outstanding
60,457,100
CFO
€-2,184.14 Mln
EBITDA
€-2,320.00 Mln
Net Profit
€-2,450.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 16.5 | -2.9 | 2.7 | 32.4 | 23.1 | 2.6 | 24.7 |
|
BSE Sensex
| 4.9 | 4.5 | 8.0 | 10.9 | 14.8 | 22.3 | 11.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 9.2 | 3.1 | -9.2 | -19.3 | 19.9 | 122.1 | 56.0 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating... pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Read more
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
Headquarters
Hellerup
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ascendis Pharma A/S - ADR stood at $ 1,947 Mln as on 31-Mar-25
The share price of Ascendis Pharma A/S - ADR is $160.33 (NASDAQ) as of 19-May-2025 16:00 EDT. Ascendis Pharma A/S - ADR has given a return of 23.08% in the last 3 years.
Ascendis Pharma A/S - ADR has a market capitalisation of $ 9,528 Mln as on 16-May-2025. As per Value Research classification, it is a company.
The P/B ratio of Ascendis Pharma A/S - ADR is 14.55 times as on 16-May-2025, a 564% premium to its peers’ median range of 2.19 times.
Since, TTM earnings of Ascendis Pharma A/S - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ascendis Pharma A/S - ADR and enter the required number of quantities and click on buy to purchase the shares of Ascendis Pharma A/S - ADR.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
The CEO & director of Mr. Jan Moller Mikkelsen. is Ascendis Pharma A/S - ADR, and CFO & Sr. VP is Mr. Jan Moller Mikkelsen.
There is no promoter pledging in Ascendis Pharma A/S - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Ascendis Pharma A/S - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-55.53
|
|
Net Margin(%)
|
-92.67
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ascendis Pharma A/S - ADR was $0 Mln.
$2.73
(
